Shares of Opko Health Inc. (NASDAQ:OPK) traded up 0% on Friday following insider buying activity. The stock traded as high as $3.70 and last traded at $3.60. 10,004,803 shares changed hands during mid-day trading, an increase of 98% from the average session volume of 5,058,523 shares. The stock had previously closed at $3.60.
Specifically, CEO Phillip Md Et Al Frost purchased 100,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was bought at an average price of $4.40 per share, with a total value of $440,000.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $13,503,384.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders bought a total of 1,394,365 shares of company stock valued at $5,231,738 in the last three months. 40.19% of the stock is owned by company insiders.
OPK has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. JPMorgan Chase & Co. lowered shares of Opko Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price for the company. in a research note on Friday, March 2nd. BidaskClub lowered shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. ValuEngine lowered shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a “buy” rating in a research note on Thursday, March 1st. Four analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Opko Health has a consensus rating of “Hold” and a consensus price target of $11.29.
The company has a market capitalization of $1,874.24, a P/E ratio of -6.43 and a beta of 1.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.14 and a quick ratio of 0.98.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB bought a new stake in Opko Health during the 4th quarter worth about $179,000. Delek Group Ltd. acquired a new stake in Opko Health in the fourth quarter valued at approximately $382,000. Meitav Dash Investments Ltd. acquired a new stake in Opko Health in the fourth quarter valued at approximately $347,000. Belpointe Asset Management LLC boosted its position in Opko Health by 30.0% in the fourth quarter. Belpointe Asset Management LLC now owns 110,500 shares of the biotechnology company’s stock valued at $541,000 after buying an additional 25,500 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in Opko Health by 18.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 340,326 shares of the biotechnology company’s stock valued at $1,668,000 after buying an additional 51,890 shares in the last quarter. 23.40% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/16/opko-health-opk-trading-0-higher-after-insider-buying-activity.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.